Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SapDM275 + AG Regimen in Metastatic Pancreatic Cancer
NCT07231094Phase 1Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SAPDM275, sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: Adverse Events at 30 days. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
SAPDM275
Beyond the preview
Go deeper on NCT07231094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231094.